These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 1026330)
1. Computer simulation of leukemia therapy: combined pharmacokinetics, intracellular enzyme kinetics, and cell kinetics of the treatment of L1210 leukemia by cytosine arabinoside. Lincoln T; Morrison P; Aroesty J; Carter G Cancer Treat Rep; 1976 Dec; 60(12):1723-39. PubMed ID: 1026330 [TBL] [Abstract][Full Text] [Related]
2. Pharmacology of combination chemotherapy of cytosine arabinoside (ara-C) and uracil arabinoside (ara-U) or tetrahydrouridine (THU) against murine leukemia L1210/0 in tumor-bearing mice. Avramis VI; Powell W Cancer Invest; 1987; 5(4):293-9. PubMed ID: 3664332 [TBL] [Abstract][Full Text] [Related]
3. Effect of 3-deazauridine on the metabolism, toxicity, and antitumor activity of azacitidine in mice bearing L1210 leukemia sensitive and resistant to cytarabine. Li ZR; Campbell J; Rustum YM Cancer Treat Rep; 1983 Jun; 67(6):547-54. PubMed ID: 6190558 [TBL] [Abstract][Full Text] [Related]
4. Combined effect of cytosine arabinoside and thiopurines. Valeriote F; Vietti T; Edelstein M Cancer Treat Rep; 1976 Dec; 60(12):1925-34. PubMed ID: 1026347 [TBL] [Abstract][Full Text] [Related]
5. Use of cell-cycle information in the preparation of drug combinations: results with cytosine arabinoside plus actinomycin D1,2. Bhuyan BK; Fraser TJ; Day KJ Cancer Treat Rep; 1976 Dec; 60(12):1813-8. PubMed ID: 1036090 [TBL] [Abstract][Full Text] [Related]
6. Characterization of tumor cell heterogeneity of a murine leukemia cell line (L1210) in response to arabinosylcytosine: quantitation using a computerized image analysis system. Raymakers RA; Slocum HK; Minderman H; Malmberg M; Rustum YM Exp Hematol; 1993 May; 21(5):602-7. PubMed ID: 8513859 [TBL] [Abstract][Full Text] [Related]
7. Correlation of mouse tissue distribution of arabinosylcytosine in vivo with enzymatic activities in vitro. Ho DH Drug Metab Dispos; 1976; 4(3):296-300. PubMed ID: 6236 [TBL] [Abstract][Full Text] [Related]
8. 1-beta-D-arabinofuranosylcytosine metabolism and incorporation into DNA as determinants of in vivo murine tumor cell response. Riva CM; Rustum YM Cancer Res; 1985 Dec; 45(12 Pt 1):6244-9. PubMed ID: 2998596 [TBL] [Abstract][Full Text] [Related]
9. [Experimental study on the correlation between the antitumor activity and pharmacokinetics of cytosine arabinoside (Ara-C) and N4-behenoyl-1-beta-D-arabinofuranosylcytosine (BH-AC)]. Takenaka T; Kimura K Nihon Gan Chiryo Gakkai Shi; 1985 Dec; 20(10):2322-8. PubMed ID: 3831176 [No Abstract] [Full Text] [Related]
10. Modulation of the metabolism and pharmacokinetics of 1-beta-D-arabinofuranosylcytosine by 1-beta-D-arabinofuranosyluracil in leukemic mice. Chandrasekaran B; Capizzi RL; Kute TE; Morgan T; Dimling J Cancer Res; 1989 Jun; 49(12):3259-66. PubMed ID: 2720678 [TBL] [Abstract][Full Text] [Related]
11. Paradoxical effect of cytosine arabinoside on mouse leukemia cell line L1210 cells. Nakayama T; Sakamoto S; Sassa S; Suzuki S; Kudo H; Nagasawa H Anticancer Res; 2005; 25(1A):157-60. PubMed ID: 15816533 [TBL] [Abstract][Full Text] [Related]
12. Disposition of cytosine arabinoside (NSC-63878) and its metabolites: a pharmacokinetic simulation. Morrison PF; Lincoln TL; Aroesty J Cancer Chemother Rep; 1975; 59(4):861-76. PubMed ID: 169990 [TBL] [Abstract][Full Text] [Related]
13. Increased activation of 1-beta-D-arabinofuranosylcytosine by hydroxyurea in L1210 cells. Walsh CT; Craig RW; Agarwal RP Cancer Res; 1980 Sep; 40(9):3286-92. PubMed ID: 7427943 [TBL] [Abstract][Full Text] [Related]
14. Effect of dose on the pharmacokinetic and pharmacodynamic effects of cytarabine. Capizzi RL; White JC; Powell BL; Perrino F Semin Hematol; 1991 Jul; 28(3 Suppl 4):54-69. PubMed ID: 1780754 [TBL] [Abstract][Full Text] [Related]
15. Phospholipid derivatives of nucleoside analogs as prodrugs with enhanced catabolic stability. Matsushita T; Ryu EK; Hong CI; MacCoss M Cancer Res; 1981 Jul; 41(7):2707-13. PubMed ID: 7248939 [TBL] [Abstract][Full Text] [Related]
16. Metabolism and chemotherapeutic activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia L1210 and evidence for its phosphorylation by deoxycytidine kinase. Brockman RW; Cheng YC; Schabel FM; Montgomery JA Cancer Res; 1980 Oct; 40(10):3610-5. PubMed ID: 6254636 [TBL] [Abstract][Full Text] [Related]
17. [Chemotherapy of the malignancies from the viewpoint of pharmacology and biochemistry of cytosine arabinoside (ara-C) and its derivatives]. Nakamura T; Ueda T Gan To Kagaku Ryoho; 1982 Aug; 9(8):1339-51. PubMed ID: 6191711 [TBL] [Abstract][Full Text] [Related]
18. Schedule-dependent synergy and antagonism between high-dose 1-beta-D-arabinofuranosylcytosine and asparaginase in the L5178Y murine leukemia. Schwartz SA; Morgenstern B; Capizzi RL Cancer Res; 1982 Jun; 42(6):2191-7. PubMed ID: 7074600 [TBL] [Abstract][Full Text] [Related]
19. Intracellular retention of cytosine arabinoside triphosphate in blast cells from children with acute myelogenous and lymphoblastic leukemia. Boos J; Hohenlöchter B; Schulze-Westhoff P; Schiller M; Zimmermann M; Creutzig U; Ritter J; Jurgens H Med Pediatr Oncol; 1996 Jun; 26(6):397-404. PubMed ID: 8614376 [TBL] [Abstract][Full Text] [Related]
20. Chemotherapy of leukemia in mice, rats, and humans relating time of humoral stimulation, tumor growth, and clinical response. Burke PJ; Karp JE; Vaughan WP J Natl Cancer Inst; 1981 Sep; 67(3):529-38. PubMed ID: 6944525 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]